Le Lézard
Classified in: Health
Subject: BLK

New Remote Mental Health Therapy Platform, mbue, Inc., Prioritizes Care For Underserved Communities, People Of Color, And Others Disproportionatley Affected By The Pandemic


NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Today, mbue, Inc., an innovative wellness resource company, announces the official launch of its effort to serve people of color and underserved communities with remote mental health therapy tailored to fit their needs. 

New remote mental health therapy platform, mbue, Inc., prioritizes care for underserved communities and people of color.

Co-Founded by entrepreneur Will Smith and startup specialist Michael Akindele, mbue, Inc. aims to disrupt the health and wellness industry by leveraging technology to reach those with the greatest need, eliminate the barriers they face to accessing care, and deliver premium quality services to its clients. The company is on a mission to make mental therapy inclusive, affordable, and convenient to those who need it most, at this critical time.

The initiative is particularly timely, considering that millions are struggling to cope and to make ends meet due to the pandemic, the resulting economic downturn, racial tensions, and social isolation.  Focusing on serving people of color and underserved communities, mbue, Inc. looks to help clients manage the day-to-day pressure and anxiety associated with these new realities. Understanding that these challenges know no borders or boundaries, mbue, Inc. employs a strategy that includes advisors and mental health practitioners on a global basis.

"The isolation and lack of social contact, the very necessary social distancing measures that will continue to be in place for some time, the loss of income, exacerbates feelings of loneliness, fear, anxiety, and can trigger depression," said Will Smith, co-founder of mbue, Inc. "In addition, parents are coping with teleworking obligations while supervising or home-schooling children, often with little down-time and in small spaces.  We are seeing many cases where the stressful context can lead to child abuse, partner abuse, and suicidal tendencies."

Some of the objectives of the mbue, Inc. team include changing the way people of color perceive mental health therapy, including removing the stigma associated with treatment rethinking how these underserved groups access mental health services, and expanding the pipeline for minority therapists.

"People can access care, be connected to a licensed therapist in a matter of days and access our service at home. mbue short for imbue, means to inspire or permeate with a feeling or quality," said Michael Akindele, co-founder of mbue, Inc.  "Our goal is to address the stigma around mental health care and provide services tailored to communities of color. We are committed to supporting inclusive, affordable and convenient mental therapy, leading to a future with increased wellness for people of all color."

Website: https://www.mbuewellness.com For more information about mbue, Inc. and the services offered, please visit:
https://www.mbuewellness.com 
mbue, Inc. can also be found on social media, including Facebook and Instagram.

SOURCE mbue, Inc.


These press releases may also interest you

at 07:55
The "KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets. A detailed...

at 07:50
The "Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method, Type of Chemical Synthesis, Contract Manufacturing Organization Size, Key Geographical Regions" report has been added to...

at 07:45
The "Laboratory Filtration Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Laboratory Filtration Equipment Market to Reach $3 Billion by 2030 The global market for Laboratory...

at 07:40
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...

at 07:35
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and...



News published on and distributed by: